European Federation for Exploratory Medicines Development (EUFEMED) - Statement on the Recent Serious Adverse Events During a Clinical Trial in Europe

BRUSSELS, January 20, 2016 /PRNewswire/ --

It is with great concern that our federation learned about the death and serious illnesses occurring in an exploratory clinical trial of a new potential medicine. Our thoughts are with the trial participants and their families.

Little is yet known about potential causes. We must await the outcomes of the ongoing investigations by the French Authorities. Once the facts are shared we will be in a position to evaluate what can be learned. Our federation will continue working with other clinical trials stakeholders - regulators, innovators, patients and researchers - to minimise risks in early development of much needed new medicines.

EUFEMED is a federation representing associations and their professional members who are involved in the early stages of the development of new medicines across Europe.

European Federation for Exploratory Medicines Development (EUFEMED)

CONTACT: Dr. Ulrike Lorch MD FRCA FFPM,,+44(0)20-8664-5200, EUFEMED:, Representing associations:AGAH, AHPPI, Club Phase I,BAPU

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234